Nine for 2019: how did we do on our predictions, and what does this mean for 2020?Year-ends prompt reflection, both on what’s happened in the last 12 months and on the year ahead. At Share XNine for 2019: how did we do on our predictions, and what does this mean for 2020?https://pharmaphorum.com/views-and-analysis/nine-for-2019-2020/
US eyes faster launch for biosimilars in North American trade pact; reportsBiosimilars could be brought to market much quicker in North America if a Trump administration proposal makes it Share XUS eyes faster launch for biosimilars in North American trade pact; reportshttps://pharmaphorum.com/news/us-eyes-shorter-exclusivity-for-biologic-drugs-in-trade-pact-report/
Celltrion gears up for subcutaneous infliximab launch in EuropeCelltrion Healthcare’s subcutaneous (SC) formulation of its infliximab biosimilar, codenamed CT-P13 SC, looks set to launch in Europe Share XCelltrion gears up for subcutaneous infliximab launch in Europehttps://pharmaphorum.com/views-analysis-market-access/celltrion-gears-up-for-subcutaneous-infliximab-launch-in-europe/
FDA approves latest Humira near-copy, as dozens of biosimilars head for marketThe FDA has approved Pfizer’s biosimilar of AbbVie’s blockbuster Humira (adalimumab), meaning that there are now five of Share XFDA approves latest Humira near-copy, as dozens of biosimilars head for markethttps://pharmaphorum.com/news/fda-approves-latest-humira-near-copy-as-dozens-of-biosimilars-head-for-market/
Sandoz buys Aspen’s Japanese generics business for up to $434 millionNovartis’ biosimilars and generics division Sandoz has agreed to buy the Japanese business of the global generics firm Share XSandoz buys Aspen’s Japanese generics business for up to $434 millionhttps://pharmaphorum.com/news/sandoz-buys-aspens-japanese-generics-business-for-up-to-434-million/
Biogen signs marketing deal for two ophthalmology biosimilarsBiogen has gained rights to market two potential ophthalmology biosimilars in major markets including the US, Europe and Share XBiogen signs marketing deal for two ophthalmology biosimilarshttps://pharmaphorum.com/news/biogen-signs-marketing-deal-for-two-ophthalmology-biosimilars/
FDA finally approves Sandoz’s Neulasta biosimilar, but will Amgen put up a fight?The FDA has approved Sandoz’s pegfilgrastim biosimilar, a cheaper version of Amgen’s long-lasting and big-selling white blood cell Share XFDA finally approves Sandoz’s Neulasta biosimilar, but will Amgen put up a fight?https://pharmaphorum.com/news/fda-finally-approves-sandozs-neulasta-biosimilar-but-will-amgen-put-up-a-fight/
Biosimilars in the UK: where are we now and where does the NHS want to go?The UK health service has well over a decade’s experience of dealing with biosimilars, but the NHS acknowledges Share XBiosimilars in the UK: where are we now and where does the NHS want to go?https://pharmaphorum.com/views-analysis-market-access/biosimilars-in-the-uk/
Novartis strikes marketing deal for Polpharma’s potential Tysabri biosimilarNovartis’ biosimilars and generics arm Sandoz has struck a deal with Polpharma Biologics to market a proposed biosimilar Share XNovartis strikes marketing deal for Polpharma’s potential Tysabri biosimilarhttps://pharmaphorum.com/news/novartis-strikes-marketing-deal-for-polpharmas-potential-tysabri-biosimilar/
